MiNK Therapeutics(US:INKT) Globenewswireยท2025-08-14 11:30Core Viewpoint - MiNK Therapeutics, Inc. reported significant clinical advancements and financial results for Q2 2025, highlighting a strengthened balance sheet and expanded funding to support its oncology and immunology programs [1][2]. Group 1: Clinical Achievements - The company demonstrated impactful clinical results, including a landmark case of durable complete remission in a patient with treatment-refractory metastatic testicular cancer following a single infusion of agenT-797 [6]. - MiNK's platform was featured in a peer-reviewed review, showcasing the potential of iNKT cells to remodel the tumor microenvironment and overcome therapeutic resistance [6]. Group 2: Financial Highlights - MiNK ended Q2 2025 with approximately $1.6 million in cash and cash equivalents, and raised an additional $13 million through equity sales, extending its cash runway beyond mid-2026 [6][7]. - The net loss for Q2 2025 was $4.2 million, or $1.06 per share, compared to a net loss of $2.7 million, or $0.73 per share for Q2 2024 [8]. - For the first half of 2025, the net loss was $7 million, or $1.76 per share, compared to $6.5 million, or $1.82 per share for the first half of 2024 [8]. Group 3: Funding and Grants - The company announced a Department of Defense STTR grant to advance the development of iNKTs for graft-versus-host disease (GvHD) prevention and treatment [5][6]. - A new clinical grant was awarded to initiate a first-in-human clinical trial of iNKTs in GvHD, with a target initiation in the second half of 2025 [5][6]. Group 4: Future Outlook - The company anticipates additional clinical readouts in 2025 from its Phase 2 trial of agenT-797 in second-line gastric cancer [6].